Inspiration Healthcare to Distribute Genedrive’s Antibiotic Induced Hearing Loss Test in UK and Ireland
We are pleased to announce that we have entered into a contract with genedrive plc, the near patient molecular diagnostics company, to distribute its Antibiotic Induced Hearing Loss test (Genedrive® MT-RNR1) in the UK and Ireland.
The Genedrive® MT-RNR1 test is the world’s first point-of-care genetic test designed for use in a neonatal intensive care setting. The test screens newborns for a genetic mutation called mt-RNR1 that can cause lifelong and irreversible deafness to a child upon administration of certain antibiotics.
Genedrive’s rapid genetic test can be completed in less than 30 minutes, allowing for correct treatment decision on antibiotics to be made within one hour of admission, as required by the UK’s National Institute of Clinical Excellence (NICE).